Literature DB >> 30403181

NPS - 2143 (hydrochloride) inhibits melanoma cancer cell proliferation and induces autophagy and apoptosis.

Shumei Wang1, Liyun Qiu2, Haiyan Song3, Ningning Dang3.   

Abstract

Melanoma is a common and aggressive skin cancer caused by the oncogenic transformation of melanocytes. NPS-2143 (hydrochloride) is a calcification drug that acts as an antagonist of the calcium-sensing receptor (CaSR) and consequently stimulates the release of parathyroid hormone. In the present work, we treated cells from the human melanoma cell line M14 to investigate the effects of NPS-2143 on melanoma cells and elucidate their underlying mechanisms. We observed that NPS-2143 inhibits the survival and proliferation of M14 cells and suppresses the migration and proliferation of M14 cells by inducing apoptosis. The Bax/Bcl‑2 ratio in M14 cells was enhanced by the NPS-2143 treatment, suggesting that the mitochondrial apoptotic pathway was activated. The expression and phosphorylation of proteins involved in the PI3K signaling pathway were altered by NPS-2143 treatment. Our data show that NPS-2143 impacts the viability and induces the apoptosis of melanoma M14 cells through its impact on the PI3K signaling pathway. It suggests that NPS-2143 could represent a promising candidate for melanoma treatment.
© 2018 médecine/sciences – Inserm.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30403181     DOI: 10.1051/medsci/201834f115

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  2 in total

1.  Calcium-Sensing Receptor Antagonist NPS-2143 Inhibits Breast Cancer cell Proliferation, Migration and Invasion via Downregulation of p-ERK1/2, Bcl-2 and Integrin β1 and Induces Caspase 3/7 Activation.

Authors:  Mohammad A Y Alqudah; Marwah Azaizeh; Aref Zayed; Leen Asaad
Journal:  Adv Pharm Bull       Date:  2021-02-01

2.  The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines.

Authors:  Kate E Lines; Anna K Gluck; Supat Thongjuea; Chas Bountra; Rajesh V Thakker; Caroline M Gorvin
Journal:  J Mol Endocrinol       Date:  2021-07-26       Impact factor: 5.098

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.